Deals channel feed – Endpoints News

Deals channel feed

Merck KGaA snatches up Geneva biotech as repurposed chemotherapy mission strikes a 'Chord'

4 years ago

Tim Lu takes Senti and its gene circuit tech public in $296M deal riding on Omid Farokhzad's SPAC

4 years ago

Novartis turns to BeiGene again for the next big checkpoint target, paying $300M to jump into TIGIT race

4 years ago

Ipsen fronts $136M to bag Genfit's once-failed NASH drug, betting on its potential in rare liver condition

4 years ago

Horizon hits the gas pedal on renewed early-stage R&D, enlisting a Mitch Gold biotech in a $1.5B+ deal

4 years ago

Mesoblast shares tank after Novartis abandons a partnership for the biotech's potential Covid-19 treatment

4 years ago

As dust settles on the Arena buyout, Pfizer exec suggests company will pursue a more aggressive M&A strategy

4 years ago

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

4 years ago

M&A season starts early? CSL seals $11.7B acquisition of Vifor Pharma

4 years ago

As year-end deals start to sizzle, CSL moves a biotech buyout to the front burner with deal expected Tuesday — report

4 years ago

Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal

4 years ago

Pfizer scoops up Arena and its S1P drug in $6.7B buyout — chasing Bristol Myers and capping a lengthy biotech turnaround

4 years ago

After investing in their Series B, Lilly bags a license for a batch of metabolic candidates

4 years ago

Billionaire BioNTech backers have been kicking the tires at Novartis' big generics arm — report

4 years ago

Viatris and Biocon mull pooling their biosimilars into a $10B standalone company — report

4 years ago

Biotech upstart gets $50M to test new virus-based therapies against solid tumors

4 years ago

'We're in': Roche and Genentech join forces on a multibillion-dollar discovery pact with a brash AI upstart

4 years ago

AstraZeneca grabs PhIII ATTR drug from Ionis — infusing $200M cash into struggling partner

4 years ago

Recordati acquires EUSA Pharma and its 4 rare disease drugs, but analysts question strategy behind the deal

4 years ago

The 2022 wave coming? Top analyst says Big Pharma will have more than $1T available to satisfy its growing appetite for biotech M&A

4 years ago

AstraZeneca nixes $8B Sobi buyout over fears a former drug would be sold to rivals — report

4 years ago

A Seattle biotech offloads lead eye drug in deal valued at $1B+ as it refocuses on emerging pipeline

4 years ago

Watch out, Roche: Novartis inks $1.5B deal to chase down prominent Parkinson’s target

4 years ago

GlaxoSmithKline, Oxford unveil new partnership pitting buzzy R&D advances against neurological disease

4 years ago

First page Previous page 66 67 686970 71 72 Next page Last page